Phathom Pharmaceuticals, Inc. Depreciation/Fixed assets

Depreciation/Fixed assets of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Depreciation/Fixed assets growth rates and interactive chart.


Highlights and Quick Summary

  • Annual Depreciation/Fixed assets for 2020 was 0.1 (a 1587.72% increase from previous year)
  • Twelve month Depreciation/Fixed assets ending September 29, 2021 was 0.18 (a 18.49% increase compared to previous quarter)
  • Twelve month trailing Depreciation/Fixed assets decreased by -29.99% year-over-year
Trailing Depreciation/Fixed assets for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
0.18 0.15 0.23 0.26
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Depreciation/Fixed assets of Phathom Pharmaceuticals, Inc.

Most recent Depreciation/Fixed assetsof PHAT including historical data for past 10 years.

Interactive Chart of Depreciation/Fixed assets of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Depreciation/Fixed assets for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 0.1
2019 0.01

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.